Evaluation of our synaptophysin results with those reported in the literature in sarcomas/mesenchymal neoplasms (see Table 2) showed that synaptophysin is most frequently expressed in CCS [15, 24, 51], DSRCT [38, 41], ES [23], and neoplasms deficient for SMARCB1 [3, 12, 18] and SMARCA4 [2, 4, 44, 46, 54]. Here, SMARCB1 is linked to sarcoma.